MX2023004802A - Compuestos espiro heterocíclicos y métodos de uso. - Google Patents
Compuestos espiro heterocíclicos y métodos de uso.Info
- Publication number
- MX2023004802A MX2023004802A MX2023004802A MX2023004802A MX2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A MX 2023004802 A MX2023004802 A MX 2023004802A
- Authority
- MX
- Mexico
- Prior art keywords
- methods
- spiro compounds
- heterocyclic spiro
- compounds
- heterocyclic
- Prior art date
Links
- -1 Heterocyclic spiro compounds Chemical class 0.000 title 1
- 150000001875 compounds Chemical class 0.000 abstract 2
- 208000001333 Colorectal Neoplasms Diseases 0.000 abstract 1
- 102100030708 GTPase KRas Human genes 0.000 abstract 1
- 206010028980 Neoplasm Diseases 0.000 abstract 1
- 206010061902 Pancreatic neoplasm Diseases 0.000 abstract 1
- 201000011510 cancer Diseases 0.000 abstract 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 abstract 1
- 239000003112 inhibitor Substances 0.000 abstract 1
- 210000004072 lung Anatomy 0.000 abstract 1
- 208000020816 lung neoplasm Diseases 0.000 abstract 1
- 239000008194 pharmaceutical composition Substances 0.000 abstract 1
- 102000004169 proteins and genes Human genes 0.000 abstract 1
- 108090000623 proteins and genes Proteins 0.000 abstract 1
- 102200006538 rs121913530 Human genes 0.000 abstract 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
- C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
- C07D487/10—Spiro-condensed systems
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D491/00—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00
- C07D491/02—Heterocyclic compounds containing in the condensed ring system both one or more rings having oxygen atoms as the only ring hetero atoms and one or more rings having nitrogen atoms as the only ring hetero atoms, not provided for by groups C07D451/00 - C07D459/00, C07D463/00, C07D477/00 or C07D489/00 in which the condensed system contains two hetero rings
- C07D491/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D513/00—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00
- C07D513/02—Heterocyclic compounds containing in the condensed system at least one hetero ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for in groups C07D463/00, C07D477/00 or C07D499/00 - C07D507/00 in which the condensed system contains two hetero rings
- C07D513/04—Ortho-condensed systems
-
- C—CHEMISTRY; METALLURGY
- C07—ORGANIC CHEMISTRY
- C07D—HETEROCYCLIC COMPOUNDS
- C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00
Landscapes
- Chemical & Material Sciences (AREA)
- Organic Chemistry (AREA)
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- General Health & Medical Sciences (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- Pharmacology & Pharmacy (AREA)
- Medicinal Chemistry (AREA)
- Animal Behavior & Ethology (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Epidemiology (AREA)
- Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
- Nitrogen Condensed Heterocyclic Rings (AREA)
- Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| CN2020123913 | 2020-10-27 | ||
| PCT/US2021/056702 WO2022093856A1 (en) | 2020-10-27 | 2021-10-26 | Heterocyclic spiro compounds and methods of use |
Publications (1)
| Publication Number | Publication Date |
|---|---|
| MX2023004802A true MX2023004802A (es) | 2023-06-22 |
Family
ID=78650109
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| MX2023004802A MX2023004802A (es) | 2020-10-27 | 2021-10-26 | Compuestos espiro heterocíclicos y métodos de uso. |
Country Status (7)
| Country | Link |
|---|---|
| US (1) | US20230406860A1 (https=) |
| EP (1) | EP4237086A1 (https=) |
| JP (1) | JP2023549055A (https=) |
| AU (1) | AU2021370660A1 (https=) |
| CA (1) | CA3199082A1 (https=) |
| MX (1) | MX2023004802A (https=) |
| WO (1) | WO2022093856A1 (https=) |
Families Citing this family (13)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| JP2023544450A (ja) | 2020-09-23 | 2023-10-23 | エラスカ・インコーポレイテッド | 三環式ピリドン及びピリミドン |
| WO2022133345A1 (en) | 2020-12-18 | 2022-06-23 | Erasca, Inc. | Tricyclic pyridones and pyrimidones |
| WO2022266206A1 (en) | 2021-06-16 | 2022-12-22 | Erasca, Inc. | Kras inhibitor conjugates |
| IL310291A (en) | 2021-07-23 | 2024-03-01 | Theras Inc | Compositions and methods for inhibition of ras |
| AR128211A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| AR128212A1 (es) * | 2022-01-06 | 2024-04-10 | Theras Inc | Composiciones y métodos para la inhibición de ras |
| CN117186107A (zh) * | 2022-05-31 | 2023-12-08 | 成都先导药物开发股份有限公司 | 一种制备2-取代-5,7-二羰基-2,6-二氮杂螺[3,4]辛烷中间体的方法 |
| CN120659773A (zh) | 2022-11-09 | 2025-09-16 | 锐新医药公司 | 化合物、复合物以及其制备方法和用途 |
| WO2026035947A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a topoisomerase payload |
| WO2026035945A1 (en) | 2024-08-07 | 2026-02-12 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a topoisomerase payload |
| WO2026064527A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Kras-targeting covalent-induced drug conjugates comprising a tubulin inhibitor payload |
| WO2026064520A1 (en) | 2024-09-19 | 2026-03-26 | Tesseract Medicines Us, Llc | Covalent-induced drug conjugates targeting kras and comprising a tubulin inhibitor payload |
Family Cites Families (17)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| WO2008017691A1 (en) | 2006-08-10 | 2008-02-14 | Glaxo Group Limited | Pyridine derivatives as sodium channel blockers |
| EP2683716A1 (en) * | 2011-03-11 | 2014-01-15 | Glaxo Group Limited | Pyrido[3,4-b]pyrazine derivatives as syk inhibitors |
| ES2898765T3 (es) * | 2015-04-10 | 2022-03-08 | Araxes Pharma Llc | Compuestos de quinazolina sustituidos y métodos de uso de los mismos |
| EP4302834A3 (en) | 2016-07-12 | 2024-07-17 | Revolution Medicines, Inc. | 2,5-disubstituted 3-methyl pyrazines and 2,5,6-trisubstituted 3-methyl pyrazines as allosteric shp2 inhibitors |
| JP7240319B2 (ja) | 2017-01-23 | 2023-03-15 | レヴォリューション・メディスンズ，インコーポレイテッド | アロステリックｓｈｐ２阻害剤としての二環式化合物 |
| KR20190110588A (ko) | 2017-01-23 | 2019-09-30 | 레볼루션 메디슨즈, 인크. | 알로스테릭 shp2 억제제로서의 피리딘 화합물 |
| US11136308B2 (en) * | 2017-01-26 | 2021-10-05 | Araxes Pharma Llc | Substituted quinazoline and quinazolinone compounds and methods of use thereof |
| AU2018273356B2 (en) | 2017-05-22 | 2021-09-16 | Amgen Inc. | KRAS G12C inhibitors and methods of using the same |
| AU2018329920B2 (en) | 2017-09-08 | 2022-12-01 | Amgen Inc. | Inhibitors of KRAS G12C and methods of using the same |
| TW201930292A (zh) | 2017-10-12 | 2019-08-01 | 美商銳新醫藥公司 | 作為變構ｓｈｐ２抑制劑的吡啶、吡嗪和三嗪化合物 |
| MX2021000887A (es) * | 2018-08-01 | 2021-03-31 | Araxes Pharma Llc | Compuestos espiroheterociclicos y metodos de uso de los mismos para el tratamiento de cancer. |
| EP3887373A1 (en) * | 2018-11-29 | 2021-10-06 | Araxes Pharma LLC | Compounds and methods of use thereof for treatment of cancer |
| MA54543A (fr) | 2018-12-20 | 2022-03-30 | Amgen Inc | Inhibiteurs de kif18a |
| JP2022513967A (ja) | 2018-12-20 | 2022-02-09 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤として有用なヘテロアリールアミド |
| AU2019401495B2 (en) | 2018-12-20 | 2025-06-26 | Amgen Inc. | Heteroaryl amides useful as KIF18A inhibitors |
| JP7686559B2 (ja) | 2018-12-20 | 2025-06-02 | アムジエン・インコーポレーテツド | Ｋｉｆ１８ａ阻害剤 |
| EP3908283A4 (en) * | 2019-01-10 | 2022-10-12 | Mirati Therapeutics, Inc. | KRAS G12C INHIBITORS |
-
2021
- 2021-10-26 WO PCT/US2021/056702 patent/WO2022093856A1/en not_active Ceased
- 2021-10-26 US US18/033,439 patent/US20230406860A1/en active Pending
- 2021-10-26 EP EP21810231.7A patent/EP4237086A1/en active Pending
- 2021-10-26 AU AU2021370660A patent/AU2021370660A1/en active Pending
- 2021-10-26 JP JP2023524901A patent/JP2023549055A/ja active Pending
- 2021-10-26 MX MX2023004802A patent/MX2023004802A/es unknown
- 2021-10-26 CA CA3199082A patent/CA3199082A1/en active Pending
Also Published As
| Publication number | Publication date |
|---|---|
| US20230406860A1 (en) | 2023-12-21 |
| JP2023549055A (ja) | 2023-11-22 |
| WO2022093856A1 (en) | 2022-05-05 |
| EP4237086A1 (en) | 2023-09-06 |
| AU2021370660A1 (en) | 2023-06-08 |
| CA3199082A1 (en) | 2022-05-05 |
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| MX2023004802A (es) | Compuestos espiro heterocíclicos y métodos de uso. | |
| MX2025004108A (es) | Inhibidores heterocíclicos anclados de proteínas kras g12c mutantes y usos de estos | |
| MX2025004109A (es) | Inhibidores heterocíclicos de las proteínas mutantes kras g12c y utilizaciones de los mismos | |
| MX2025013001A (es) | Inhibidores espiro-heterocíclicos de las proteínas mutantes kras g12c y usos de los mismos. | |
| SA521422405B1 (ar) | Mat2a مثبطات أزا-غير متجانسة ثنائية الحلقة لـ وطرق الاستخدام لعلاج السرطان | |
| PH12022552739A1 (en) | Fused tricyclic kras inhibitors | |
| JOP20210317A1 (ar) | مثبطات غير متجانسة ثنائية الحلقة لـ mat2a وطرق استخدامها لعلاج السرطان | |
| MX2025013504A (es) | Inhibidores de kras de anillo fundido para el tratamiento de enfermedades | |
| PH12021551493A1 (en) | Aza-heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| EP4552631A3 (en) | Combination of dasatinib and adagrasib for use in the treatment of non-small cell lung cancer | |
| NZ795548A (en) | Allosteric egfr inhibitors and methods of use thereof | |
| WO2019191470A8 (en) | Heterobicyclic inhibitors of mat2a and methods of use for treating cancer | |
| GEP20247710B (en) | Small molecule inhibitors of kras g12c mutant | |
| PH12020552004A1 (en) | Heterocyclic compounds as kinase inhibitors, compositions comprising the heterocyclic compound, and methods of use thereof | |
| MX2021004624A (es) | Derivados de 2-(2-acriloil-2,6-diazaspiro[3.4]octan-6-il)-6-(1h-in dazol-4-il)-benzonitrilo y compuestos relacionados como inhibidores de la proteina kras mutante g12c para inhibir metastasis de tumor. | |
| ZA202201499B (en) | Dual atm and dna-pk inhibitors for use in anti-tumor therapy | |
| AU2020281332A8 (en) | Dna-dependent protein kinase inhibitor | |
| MX2024013838A (es) | Compuestos y usos de estos | |
| PH12021553233A1 (en) | Imidazopyrimidines as eed inhibitors and the use thereof | |
| EA201400111A1 (ru) | Ингибиторы mek и способы их применения | |
| ZA202304734B (en) | Alpha protein kinase 1 inhibitors and methods of use | |
| PH12022551623A1 (en) | Substituted pyrazolo-pyrimidines and uses thereof | |
| JOP20220107A1 (ar) | مثبطات egfr تفارغية وطرق استخدامها | |
| MX2021011524A (es) | Inhibidores de proteina arginina n-metiltransferasa 5 (prmt5) y usos de los mismos. | |
| MX2025014397A (es) | Inhibidores de helicasa de adn recq del sindrome de werner (wrn) |